Editorial: Innovative immunotherapy strategies for enhanced treatment of Hodgkin and non-Hodgkin lymphomas

Editorial: Innovative immunotherapy strategies for enhanced treatment of Hodgkin and non-Hodgkin lymphomas

Saved in:

Bibliographic Details
Main Authors:	Michael J. Robertson, Eric Vivier, Penny Fang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Immunology
Subjects:	lymphoma immunotherapy CAR (chimeric antigen receptor) T-cell therapy immune checkpoint inhibitors monoclonal Abs
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1642505/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Immunotherapy resistance and advancing adaptive cell therapeutics
by: Luciana Rodrigues Carvalho Barros, et al.
Published: (2025-06-01)

Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases
by: Mingwei Jiang, et al.
Published: (2025-12-01)

Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells
by: Yang Liu, et al.
Published: (2025-01-01)

Emerging Clinical Perspectives of Immunotherapy in Triple Negative Breast Cancer: A Comprehensive Review
by: Sparshita Dey, et al.
Published: (2025-06-01)

Study of the suppression of a tumor growth expressing a carcinoembryonic antigen with a new high-tech drug carplasmin (CAR-T therapy) in Balb/c nude mice
by: V. K. Bozhenko, et al.
Published: (2023-04-01)

Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trialResearch in context
by: Armin Ghobadi, et al.
Published: (2025-03-01)

Hepatic T cell lymphoma after chimeric antigen receptor T cell therapy for myeloma
by: Joshua Mehr, et al.
Published: (2024-12-01)

Therapeutic landscape of ovarian cancer: recent advances and emerging therapies
by: Ling Wang, et al.
Published: (2025-08-01)

Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies
by: Xiaoshuang Yuan, et al.
Published: (2025-05-01)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
by: Eugenio Galli, et al.
Published: (2021-10-01)

Nano-immunotherapy for lung cancer
by: Yuting Lu, et al.
Published: (2023-03-01)

Direct visualization of chimeric antigen receptors on primary human T cells using dSTORM super-resolution microscopy
by: Leon Gehrke, et al.
Published: (2025-08-01)

CD-19-directed immunotherapy resistance mechanisms of B-precursor acute lymphoblastic leukemia
by: E. V. Glukhanyuk, et al.
Published: (2019-01-01)

CD19‐targeting chimeric antigen receptor T‐cell therapy is safe and effective for intra‐cardiac B cell non‐Hodgkin lymphoma
by: Daniel H. Chen, et al.
Published: (2024-12-01)

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas
by: Gohar S. Manzar, et al.
Published: (2025-01-01)

Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory/relapsed primary or secondary central nervous system lymphoma
by: Jiaying Wu, et al.
Published: (2024-11-01)

CAR-T: from bench to bedside
by: M. О. Popova, et al.
Published: (2024-09-01)

Chimeric Autoantibody Receptor- and/or Peptide-MHC-Based CAR Therapies for Targeted Elimination of Antigen-Specific B or T Cells in Hypersensitivity Disorders Such as Allergies and Autoimmune Diseases
by: Isidora Protić-Rosić, et al.
Published: (2025-05-01)

Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review
by: Ahsen Morva, et al.
Published: (2025-06-01)

GD2-CAR NK-92 cell activity against neuroblastoma cells is insusceptible to TIGIT knockout
by: Wiebke Jünemann, et al.
Published: (2025-05-01)

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
by: Jingjing Zhao, et al.
Published: (2023-12-01)

γδT cells, a key subset of T cell for cancer immunotherapy
by: Jianzhen Lv, et al.
Published: (2025-03-01)

Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy
by: Rose Ghemrawi, et al.
Published: (2024-09-01)

EXPERIENCE IN THE TREATMENT OF REFRACTORY HODGKIN’S LYMPHOMA
by: A. M. Chervontseva, et al.
Published: (2021-03-01)

Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases
by: Alejandrina Hernández-López, et al.
Published: (2025-01-01)

An integral membrane constitutively active heparanase enhances the tumor infiltration capability of NK cells
by: Sofia Liborio-Ramos, et al.
Published: (2025-12-01)

Engineered bacteria assist CAR-cell immunotherapy
by: Tianyu Shao, et al.
Published: (2025-03-01)

Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysis
by: Jinhuan Xu, et al.
Published: (2025-01-01)

Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM
by: Danielle R. Cook, et al.
Published: (2025-07-01)

“A.B.C.” of Immunotherapy in Hematological Malignancies…Promise and Perils
by: Jyoti Bajpai, et al.
Published: (2024-04-01)

The use of immunotherapy for the treatment of refractory forms of Hodgkin lymphoma in real clinical practice.
by: I. A. Kamaeva, et al.
Published: (2021-06-01)

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematology
by: Alina Ershova, et al.
Published: (2025-07-01)

From lab to lifesaver: the rise of CAR T-cell therapy in oncology
by: Shriyash S. Jangavali, et al.
Published: (2025-05-01)

Transduction of γδ T cells with Baboon envelope pseudotyped lentiviral vector encoding chimeric antigen receptors for translational and clinical applications
by: Lorraine Pinot, et al.
Published: (2025-06-01)

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
by: Anna De Lucia, et al.
Published: (2025-02-01)

Tandem CAR-T cell therapy: recent advances and current challenges
by: Sara Gómez-Melero, et al.
Published: (2025-02-01)

CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy
by: Filipa D. dos Reis, et al.
Published: (2025-05-01)

Prognostic value of early post-treatment 18F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy
by: Seyed Ali Mirshahvalad, et al.
Published: (2025-06-01)

PATHOBIOLOGY OF HODGKIN LYMPHOMA
by: Claudio Agostinelli, et al.
Published: (2014-06-01)

A new therapeutic pathway in autoimmune diseases: chimeric antigen receptor T cells (CAR-T) targeting specific cell subtypes or antigen-specific B lymphocytes—a brief review
by: María Fernanda Segovia, et al.
Published: (2025-03-01)